Securities code: 688317 securities abbreviation: Shanghai Zj Bio-Tech Co.Ltd(688317) Announcement No.: 2022-013 Shanghai Zj Bio-Tech Co.Ltd(688317)
Suggestive announcement on the change of equity of Pan Xin (Shanghai) Equity Investment Center (limited partnership), a shareholder holding more than 5%
The board of directors, all directors and relevant shareholders of the company guarantee that there are no false records, misleading statements or major omissions in the contents of the announcement, and bear legal responsibility for the authenticity, accuracy and integrity of its contents in accordance with the law.
Important content tips:
This equity change belongs to the reduction of holdings and does not touch the tender offer;
After this equity change, Panxin (Shanghai) Equity Investment Center (limited partnership) (hereinafter referred to as "Panxin investment" or "information disclosure obligor") holds 9735062 shares of Shanghai Zj Bio-Tech Co.Ltd(688317) (hereinafter referred to as "the company"), accounting for 4.9999% of the total shares of the company;
Panxin investment does not belong to the controlling shareholder of the company, and this equity change will not lead to changes in the controlling shareholder and actual controller of the company.
On February 24, 2022, the company received the short form equity change report issued by the shareholder Panxin investment, and now announces its relevant equity changes as follows:
1、 Changes in equity this time
(I) basic information of information disclosure obligor
As of the disclosure date of this announcement, the basic information of information disclosure obligors is as follows:
Company name: Panxin (Shanghai) Equity Investment Center (limited partnership)
Type of enterprise: limited partnership
Registered address: room 249, No. 4-5, Lane 37, Zhangjiabang Road, China (Shanghai) pilot Free Trade Zone
Date of establishment: August 30, 2011
Operation period: August 29, 2026
Executive partner Shanghai Yude equity investment center (limited partnership)
Executive partner appoints representative Tian Yu
Unified social credit Code: 91310000582062390q
Business scope: equity investment, industrial investment, investment management, investment consulting. [for projects subject to approval according to law, business activities can be carried out only after approval by relevant departments]
Mailing address: 15 / F, Jinbao building, No. 89 Jinbao Street, Dongcheng District, Beijing
Major partners and capital contributions:
No. partner name subscribed capital contribution subscribed capital contribution ratio (10000 yuan) example (%)
1 Shanghai Yude equity investment center (limited partnership) 1 0.0002
2 Beijing Xinyu Investment Center (limited partnership) 506223 99.9998
Total - 506224 100
Note: the discrepancy between the total and the mantissa of the sum of the sub item values is caused by rounding. (II) changes in equity
In this equity change, the details of the equity change of the information disclosure obligor are as follows:
Price range in total share capital shareholder name reduction method change time reduction number of shares (shares)
(yuan / share) ratio
2022.2.22–
Panxin investment centralized bidding 37.12-38.29 513000 0.26% 2022.2.23
Total / / 513000 0.26%
remarks:
1. All the shares involved in this equity change enjoy voting rights, and there are no restrictions on the transfer of voting rights, such as delegation or restriction of voting rights.
2. This change does not violate the securities law of the people's Republic of China, the measures for the administration of the acquisition of listed companies and other laws and regulations, the business rules of Shanghai Stock Exchange and other relevant provisions and relevant commitments.
2、 Before and after this equity change, the information discloser's shares in the company's equity
Shares held before this change shares held after this change
Shareholder name share nature shareholding quantity shareholding quantity
Shareholding ratio shareholding ratio (share) (share)
Panxin (Shanghai) equity investment unlimited sales clause
10,248,062 5.26% 9,735,062 4.9999%
Asset Center (limited partnership with pieces of tradable shares)
remarks:
All the shares of the company held by the information disclosure obligor after this equity change enjoy voting rights, and there are no rights restrictions or restricted transfers such as voting rights entrustment or restriction.
3、 Follow up matters involved
1. This equity change is a reduction of holdings and does not touch the tender offer.
2. According to the provisions of laws, regulations and normative documents such as the securities law of the people's Republic of China, the measures for the administration of the acquisition of listed companies and the standards for the contents and forms of information disclosure by companies offering securities to the public No. 15 - Report on changes in equity, this change in equity involves the disclosure of a simplified report on changes in equity by the information disclosure obligor, For details, please refer to the website of Shanghai Stock Exchange on the same day (www.sse. Com. CN.) The Shanghai Zj Bio-Tech Co.Ltd(688317) simplified equity change report disclosed.
3. This equity change is the normal reduction of shareholders' holdings and will not have a significant impact on the corporate governance structure and sustainable operation. This equity change will not lead to the change of controlling shareholders and actual controllers.
4. After this equity change, the information disclosure obligor is still in the reduction period. The company will urge it to strictly implement the relevant provisions on reducing its holdings and disclose relevant information to investors in time. Please pay attention to investment risks. It is hereby announced.
Shanghai Zj Bio-Tech Co.Ltd(688317) board of directors February 25, 2022
